Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

26 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2.
Brooks P, Emery P, Evans JF, Fenner H, Hawkey CJ, Patrono C, Smolen J, Breedveld F, Day R, Dougados M, Ehrich EW, Gijon-BaƱos J, Kvien TK, Van Rijswijk MH, Warner T, Zeidler H. Brooks P, et al. Among authors: ehrich ew. Rheumatology (Oxford). 1999 Aug;38(8):779-88. doi: 10.1093/rheumatology/38.8.779. Rheumatology (Oxford). 1999. PMID: 10501435
Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protocol 035 Study Group.
Cannon GW, Caldwell JR, Holt P, McLean B, Seidenberg B, Bolognese J, Ehrich E, Mukhopadhyay S, Daniels B. Cannon GW, et al. Arthritis Rheum. 2000 May;43(5):978-87. doi: 10.1002/1529-0131(200005)43:5<978::AID-ANR4>3.0.CO;2-0. Arthritis Rheum. 2000. PMID: 10817549 Clinical Trial.
26 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page